Plain-English translation of NCT05908695 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer's Disease research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a medication called sodium oligomannate () to see if it can help slow memory loss and thinking problems in people with mild to moderate Alzheimer's disease. Researchers want to confirm whether this treatment actually works, understand how it works in the brain, and identify any side effects from long-term use. About half of participants will receive the medication while the other half receive a placebo (inactive pill) to fairly compare results.
Current Alzheimer's treatments have limited effectiveness, and doctors need new options to help patients maintain their thinking and memory abilities. This trial will provide important information about whether this medication could become a useful tool for people newly diagnosed with Alzheimer's disease.
You likely qualify if…
You likely don't qualify if…
This is a 36-week study where you will visit the research center multiple times for check-ups, memory tests, brain scans, and heart monitoring. You will take either the study medication or a placebo pill daily at home, and neither you nor your doctor will know which one you're receiving until the study ends. Your caregiver will help track how you're doing, and the research team will monitor you closely for any side effects or changes in your memory and thinking abilities.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
China